Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. Trade-Ideas LLC identified Opko Health ( OPK) as a "perilous reversal" (up big yesterday but down big today) candidate. In addition to specific proprietary factors, Trade-Ideas identified Opko Health as such a stock due to the following factors:
- OPK has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $34.9 million.
- OPK has traded 3.5 million shares today.
- OPK is down 3.3% today.
- OPK was up 7.7% yesterday.
EXCLUSIVE OFFER: Get the inside scoop on opportunities in OPK with the Ticky from Trade-Ideas. See the FREE profile for OPK NOW at Trade-Ideas More details on OPK: Opko Health, Inc., a pharmaceutical and diagnostics company, engages in the discovery, development, and commercialization of novel and proprietary technologies. It operates in two segments, Pharmaceuticals and Diagnostics. Currently there are 3 analysts that rate Opko Health a buy, no analysts rate it a sell, and none rate it a hold. The average volume for Opko Health has been 4.9 million shares per day over the past 30 days. Opko Health has a market cap of $3.9 billion and is part of the health care sector and health services industry. The stock has a beta of 1.05 and a short float of 20.9% with 9.35 days to cover. Shares are up 98.5% year to date as of the close of trading on Wednesday. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more. TheStreetRatings.com Analysis: TheStreet Quant Ratings rates Opko Health as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share and deteriorating net income. Highlights from the ratings report include:
- OPK's very impressive revenue growth greatly exceeded the industry average of 10.4%. Since the same quarter one year prior, revenues leaped by 74.7%. This growth in revenue does not appear to have trickled down to the company's bottom line, displayed by a decline in earnings per share.
- Compared to its closing price of one year ago, OPK's share price has jumped by 132.33%, exceeding the performance of the broader market during that same time frame. Regarding the stock's future course, our hold rating indicates that we do not recommend additional investment in this stock despite its gains in the past year.
- OPKO HEALTH INC has experienced a steep decline in earnings per share in the most recent quarter in comparison to its performance from the same quarter a year ago. Earnings per share have declined over the last two years. We anticipate that this should continue in the coming year. During the past fiscal year, OPKO HEALTH INC reported poor results of -$0.10 versus -$0.03 in the prior year. For the next year, the market is expecting a contraction of 140.0% in earnings (-$0.24 versus -$0.10).
- The company, on the basis of change in net income from the same quarter one year ago, has significantly underperformed when compared to that of the S&P 500 and the Biotechnology industry. The net income has significantly decreased by 522.0% when compared to the same quarter one year ago, falling from -$9.65 million to -$60.00 million.
- You can view the full Opko Health Ratings Report.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.